Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimenCalvin J Cohen, Nathan Clumeck, Jean-Michel Molina, et al.
The Journal of Antimicrobial Chemotherapy|June 10, 2011
96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baselineNathan Clumeck, Armin Rieger, Denes Banhegyi, et al.
AIDS (London, England)|May 21, 2005
TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trialKeikawus Arastéh, Nathan Clumeck, Anton Pozniak, et al.
AIDS (London, England)|January 15, 2016
High-risk human papillomavirus genotypes distribution in a cohort of HIV-positive women living in Europe: epidemiological implication for vaccination against human papillomavirusDeborah Konopnicki, Yannick Manigart, Christine Gilles, et al.
The Journal of Infectious Diseases|May 13, 2009
A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1Michael Saag, James Goodrich, Gerd Fätkenheuer, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 3, 2006
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study)Anthony Lamarca, Nathan Clumeck, Andreas Plettenberg, et al.
HIV Clinical Trials|February 11, 2003
Comparison of metabolic abnormalities and clinical lipodystrophy 48 weeks after switching from HAART to Trizivir versus continued HAART: the Trizal studyAlain Lafeuillade, Nathan Clumeck, Josep Mallolas, et al.
Antiviral Therapy|May 29, 2008
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) studyJudith Currier, Adriano Lazzarin, Louis Sloan, et al.
Journal of the International AIDS Society|February 15, 2013
High-risk human papillomavirus infection in HIV-positive African women living in EuropeDeborah Konopnicki, Yannick Manigart, Christine Gilles, et al.
The Journal of Infectious Diseases|March 7, 2013
Sustained viral suppression and higher CD4+ T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive womenDeborah Konopnicki, Yannick Manigart, Christine Gilles, et al.
Pageof 7